ClinicalTrials.gg
Sign In
CompletedNCT06212921BIPAMIUpdated Nov 6, 2026

Biomarkers in Prediction of AMI

An interventional study of Sequential blood samples in Acute Mesenteric Ischemia, sponsored by University of Tartu. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by University of Tartu · Not applicable, Interventional, and Diagnostic

Updated Nov 6, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
256
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Current study will be undertaken to identify combinations of biomarkers that can reliably identify acute mesenteric ischaemia (AMI) and distinguish between non-transmural and transmural ischaemia. Different combinations of biomarkers for different sub-types and severity of AMI, and different time points of measurement after onset of symptoms.

02

Conditions studied

  • Acute Mesenteric Ischemia

Browse trials for

03

In context

Mesenteric Ischemia

40 studies on the registry are indexed under Mesenteric Ischemia; 14 are open to participants now.

This study's enrollment of 256 is above the median of 110 across 14 interventional studies indexed under Mesenteric Ischemia.

Browse Mesenteric Ischemia studies →

Lead sponsor

University of Tartu is the lead sponsor of 46 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Initial decision in favour of further diagnostics of mesenteric ischaemia

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Consent declined by patient or next of kin (delayed consent)
  • Chronic mesenteric ischaemia without an acute event
  • Immediate decision for withdrawal of further diagnostics and active treatment
  • Referral from another hospital with already established diagnosis of AMI
  • AMI diagnosed at surgery without previously having been considered
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
256 participants (actual)

Study arms

  • Other
    Patient with suspicion of acute mesenteric ischaemia

    Bolld samples is the only intervention. All patients with suspicion of AMI will be included and blood samples collected

    Diagnostic Test: Sequential blood samples

Interventions

  • Diagnostic testSequential blood samples

    Sequential blood samples for diagnostic tests is the only intervention in thei study

06

What researchers measure

Primary outcomes

  1. Rate of correctly predicted cases of acute mesenteric ischaemia

    Rate of correctly predicted cases of Acute mesenteric ischaemia using different biomarkers

    Time frame: 10 months

07

Study locations

2 sites
08

References and documents

Publications

  • Tamme K, Acosta S, Biloslavo A, Bjorck M, Casian D, Damaskos D, Forbes A, Kase K, Kisand K, Lakbar I, Mihnovits V, Murruste M, Mandul M, Nuzzo A, Padar M, Starkopf J, Visconti D, Reintam Blaser A. Biomarkers In Prediction of Acute Mesenteric Ischaemia: a prospective multicentre study (BIPAMI study): a study protocol. BMC Surg. 2024 Jul 3;24(1):201. doi: 10.1186/s12893-024-02491-3. PubMed 38961419 ↗

Individual participant data

Plan to share: No

09

Updates

1 registry update since Sep 25, 2026
Status
Recruiting→Completed
changed Nov 6, 2026
Sites
1 site added, 1 site removed
Show site
  • Lucerne Cantonal Hospital · Lucerne, Switzerland
Show 1 removed
  • Lucerne Cantonal Hospital · Luzern, Switzerland
Nov 6, 2026
Primary completion
Sep 2025→Dec 31, 2025 (actual)
Nov 6, 2026
Enrollment
250 (estimated)→256 (actual)
Nov 6, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38961419 ↗
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38961419 ↗
    1 site added, 1 site removed
    Show site
    • Lucerne Cantonal Hospital · Lucerne, Switzerland
    Show 1 removed
    • Lucerne Cantonal Hospital · Luzern, Switzerland
    Primary completion Sep 2025→Dec 31, 2025 (now actual)
    Enrollment 250 (estimated)→256 (actual)
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06212921
Lead sponsor
University of Tartu
Responsible party
Annika Reintam Blaser (Associate Professor, University of Tartu) — Principal investigator
First posted
Jan 19, 2024
Start date
Oct 14, 2024
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Mesenteric Ischemia →

Other studies from this sponsor

University of Tartu

Start the discussion